Reducing extramedical use and harms of pharmaceutical opioids: the potential role of abuse-deterrent formulations
Louisa Degenhardt, Briony Larance, Amy Peacock, Michael Farrell
The Lancet Psychiatry | ELSEVIER SCI LTD | Published : 2015
Awarded by NHMRC
LD and BL are supported by NHMRC research fellowships (#1041472 and #1073858 respectively). The National Drug and Alcohol Research Centre at UNSW Australia is supported by funding from the Australian Government under the Substance Misuse Prevention and Service Improvements Grant Fund. LD, BL, AP and MF received untied educational grant funding from Mundipharma for the conduct of post-marketing surveillance of a new formulation of oxycodone in Australia (the NOMAD study). BL and LD have received untied educational grants from Reckitt Benckiser for the post-marketing surveillance of opioid substitution therapy medications in Australia, the development of an opioid-related behaviour scale, and a study of opioid substitution therapy uptake among chronic non-cancer pain patients. These funders had no role in the design, conduct, analysis, interpretation nor in our decision to publish the studies' findings. These funders had no knowledge of this Comment.